Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
BackgroundIt is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this associatio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2022.963265/full |
| _version_ | 1818474777499664384 |
|---|---|
| author | Ping’an Ding Ping’an Ding Honghai Guo Honghai Guo Chenyu Sun Shuya Chen Peigang Yang Peigang Yang Yuan Tian Yuan Tian Scott Lowe Qun Zhao Qun Zhao |
| author_facet | Ping’an Ding Ping’an Ding Honghai Guo Honghai Guo Chenyu Sun Shuya Chen Peigang Yang Peigang Yang Yuan Tian Yuan Tian Scott Lowe Qun Zhao Qun Zhao |
| author_sort | Ping’an Ding |
| collection | DOAJ |
| description | BackgroundIt is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this association lacks sufficient evidence in patients with gastrointestinal stromal tumours (GIST). Therefore, this study aimed to investigate whether the Cr/CysC ratio was associated with sarcopenia and recurrence-free survival (RFS) in patients with GIST.Materials and methodsThe study retrospectively analysed 413 patients with GIST who underwent surgical resection from January 2016 to January 2020. The serum Cr/CysC ratio was determined as a proxy for sarcopenia by comparing it with various biomarkers and Cox multifactorial analysis was used to determine the relationship between Cr/CysC ratio and prognosis.ResultsSerum Cr/CysC was positively correlated with skeletal muscle area (SMA) (r = 0.256, p < 0.001), skeletal muscle index (SMI) (r = 0.300, p < 0.001), and hand grip strength (HGS) (r = 0.251, p < 0.001). The area under the receiver operator characteristic curve for sarcopenic subjects with serum Cr/CysC ratio was significantly greater than other biomarkers (Cr/CysC: 0.840, CysC: 0.732, Cr: 0.518). The optimal cut-off value for Cr/CysC was 0.65, and patients in the high Cr/CysC group had a higher 3-year recurrence-free survival (RFS) than those in the low Cr/CysC group (92.72 vs. 72.46%, p < 0.001). Cox multifactorial analysis found that the Cr/CysC ratio was an independent risk factor for RFS in GIST patients (HR = 2.143, 95% CI: 1.431–5.459, p = 0.011).ConclusionSerum Cr/CysC ratio has satisfactory and comparable diagnostic accuracy, and prognostic value for sarcopenia in patients with GIST. Therefore, it can be a simple and practical clinical tool to screen sarcopenia in GIST patients. However, further studies are required to validate these findings. |
| first_indexed | 2024-04-14T04:40:49Z |
| format | Article |
| id | doaj.art-6032e08d231f4107955cba5a0ff9545c |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-14T04:40:49Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-6032e08d231f4107955cba5a0ff9545c2022-12-22T02:11:40ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-09-01910.3389/fnut.2022.963265963265Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumoursPing’an Ding0Ping’an Ding1Honghai Guo2Honghai Guo3Chenyu Sun4Shuya Chen5Peigang Yang6Peigang Yang7Yuan Tian8Yuan Tian9Scott Lowe10Qun Zhao11Qun Zhao12The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaHebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, ChinaThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaHebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, ChinaAMITA Health Saint Joseph Hospital Chicago, Chicago, IL, United StatesNewham University Hospital, London, United KingdomThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaHebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, ChinaThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaHebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, ChinaCollege of Osteopathic Medicine, Kansas City University, Kansas City, MO, United StatesThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, ChinaHebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, ChinaBackgroundIt is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this association lacks sufficient evidence in patients with gastrointestinal stromal tumours (GIST). Therefore, this study aimed to investigate whether the Cr/CysC ratio was associated with sarcopenia and recurrence-free survival (RFS) in patients with GIST.Materials and methodsThe study retrospectively analysed 413 patients with GIST who underwent surgical resection from January 2016 to January 2020. The serum Cr/CysC ratio was determined as a proxy for sarcopenia by comparing it with various biomarkers and Cox multifactorial analysis was used to determine the relationship between Cr/CysC ratio and prognosis.ResultsSerum Cr/CysC was positively correlated with skeletal muscle area (SMA) (r = 0.256, p < 0.001), skeletal muscle index (SMI) (r = 0.300, p < 0.001), and hand grip strength (HGS) (r = 0.251, p < 0.001). The area under the receiver operator characteristic curve for sarcopenic subjects with serum Cr/CysC ratio was significantly greater than other biomarkers (Cr/CysC: 0.840, CysC: 0.732, Cr: 0.518). The optimal cut-off value for Cr/CysC was 0.65, and patients in the high Cr/CysC group had a higher 3-year recurrence-free survival (RFS) than those in the low Cr/CysC group (92.72 vs. 72.46%, p < 0.001). Cox multifactorial analysis found that the Cr/CysC ratio was an independent risk factor for RFS in GIST patients (HR = 2.143, 95% CI: 1.431–5.459, p = 0.011).ConclusionSerum Cr/CysC ratio has satisfactory and comparable diagnostic accuracy, and prognostic value for sarcopenia in patients with GIST. Therefore, it can be a simple and practical clinical tool to screen sarcopenia in GIST patients. However, further studies are required to validate these findings.https://www.frontiersin.org/articles/10.3389/fnut.2022.963265/fullserum creatinineserum cystatin Cserum Cr/CysC ratiosarcopeniagastrointestinal stromal tumors |
| spellingShingle | Ping’an Ding Ping’an Ding Honghai Guo Honghai Guo Chenyu Sun Shuya Chen Peigang Yang Peigang Yang Yuan Tian Yuan Tian Scott Lowe Qun Zhao Qun Zhao Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours Frontiers in Nutrition serum creatinine serum cystatin C serum Cr/CysC ratio sarcopenia gastrointestinal stromal tumors |
| title | Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| title_full | Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| title_fullStr | Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| title_full_unstemmed | Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| title_short | Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| title_sort | serum creatinine cystatin c ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours |
| topic | serum creatinine serum cystatin C serum Cr/CysC ratio sarcopenia gastrointestinal stromal tumors |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2022.963265/full |
| work_keys_str_mv | AT pinganding serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT pinganding serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT honghaiguo serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT honghaiguo serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT chenyusun serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT shuyachen serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT peigangyang serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT peigangyang serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT yuantian serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT yuantian serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT scottlowe serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT qunzhao serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours AT qunzhao serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours |